Drug Profile

GS 0174

Alternative Names: FSI-174; GS-0174

Latest Information Update: 07 Nov 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Forty Seven
Developer Gilead Sciences
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Haematological malignancies

Most Recent Events

07 Nov 2022 Discontinued - Phase-I for Haematological malignancies in USA (Parenteral) (Gilead Sciences pipeline, November 2022)
18 Feb 2021 Phase-I clinical trials in Haematological malignancies in USA (Parenteral) (Gilead Science pipeline, February 2021)
07 Apr 2020 Gilead Sciences completes acquisition of Forty Seven

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com